CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Recruiting· 52 target
Drug / intervention
Thiamine +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06322212
NCT06322212Early Ph 1RecruitingOn TrackUpdated 3mo ago
CompareCT.gov

Type 2 Diabetes Mellitus and Blood Brain Barrier Improvement - A Randomized Clinical Trial

University of California, Los Angeles·interventional·Posted Mar 20, 2024·Updated Mar 13, 2026

In Brief

A Early Phase 1 clinical trial evaluating Thiamine and Placebo for Type2diabetes. Currently recruiting, targeting 52 participants across 1 site.

Detailed Summary

The majority of T2DM adults show thiamine (vitamin B1) deficiency which may contribute to impaired function. This study will examine patients with T2DM through brain MRI scans, cognition assessments, blood tests, and questionnaires. Our goal is to see if a thiamine treatment (taking vitamin B1 capsules) can improve function. Patients will be asked to come to UCLA two times three months apart and each visit will last about 2.5-3 hours.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType2diabetes
CountriesUnited States
CollaboratorsNational Institute on Aging (NIA)

Timeline

Early Ph 1Recruiting
202520262027
First PostedMar 20, 2024
Enrollment StartAug 1, 2024
Primary CompletionDec 31, 2026
Study CompletionMar 31, 2027
TodayJul 1, 2026
Enrollment to primary: 2.4 yearsPosted 2.3 years agoPrimary completion in 6 months

Interventions

Thiaminedietary

Participants will be provided instruction to take one 500 mg capsule of Thiamine (Vitamin B1) each day in the morning for 3-months.

Placeboother

Participants will be provided instruction to take one capsule (placebo) each day in the morning for 3-months.